Background: One of the animal angiogenesis with high inflammation and rapid growth is Ehrlich ascites carcinoma. Balanites aegyptiaca seeds extract (BASE), a new synthesized compound has antioxidant and antidiabetic activity. The purpose of this study was to evaluate anti-angiogenic activity of BASE in ehrlich ascites carcinoma (EAC)-bearing mice. Materials and Methods: BASE was prepared and characterized using instrumental analysis and spectral data. Furthermore, the IC50 of BASE against the renal carcinoma cell line (RCC-949) was calculated. Adult albino mice weighing 25±5 g was used to assess the anti-angiogenic activity of BASE (100 and 200 mg kg‾1 body weight) in EAC-bearing mice. Results: IC50 of BASE against the renal carcinoma cell line (RCC-949) was equal to 62.18 µg mL‾1. The daily oral administration of BASE at concentrations of 100 and 200 mg kg‾1 body weight for 30 days to EAC-bearing mice resulted in a significant improvement in tumor volume and tumor weight, urea, creatinine, uric acid, TNF-α, NOx, TBARs, GSH, CAT, SOD, GPx and VEGF-C gene expression in EAC-bearing mice. Furthermore, BASE almost normalized these effects in renal histoarchitecture. Conclusion: The BASE has anti-angiogenic activity in EAC-bearing mice.
PDF Fulltext XML References Citation
How to cite this article